“Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL”, J of Skin, vol. 9, no. 6, p. s618, Nov. 2025, doi: 10.25251/t4rkzz84.